Modalis Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
43 Foundry Ave, Waltham, Massachusetts, ...Phone Number
(617) 219-9808Website
www.modalistx.comRevenue
$20 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
1
1
About Modalis Therapeutics
Modalis Therapeutics Corporation is a biotech company focused on developing treatments for genetic diseases using its proprietary genome editing platform, CRISPR-GNDM. The company specializes in epigenome editing technology that selectively targets and controls specific genes to treat diseases. Their innovative approach aims to restore the precise orchestration of protein production in the body, which is crucial for maintaining health. The intended clients include patients suffering from genetic disorders, as well as potential partners for collaborative development.Explore more
Modalis Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Modalis Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Modalis Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Modalis Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Modalis Therapeutics
Funding: Get notified immidiatlly once Modalis Therapeutics has new funding data
Check if Modalis Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Modalis Therapeutics is spiking on competitors!
Click to see if Modalis Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Modalis Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Modalis Therapeutics
Find 3 more new buyers
Company Profile Activity
Activity Insights
Modalis Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Modalis Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Modalis Therapeutics.
Modalis Therapeutics financials insights
Gather financial insights about Modalis Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series B
$15M
Series A
$11M
Modalis Therapeutics Tech Stack
A closer look at the technologies used by Modalis Therapeutics
Most Recent Scoops
Event
Product Marketing, Events, Business Intelligence, Engineering, Analytics & Insights, Research & Development, Sales, Search, Software, Bioengineering, Laboratory Operations, Clinical Operations, Field Marketing, Operations
Event
Events, Training, Learning & Development, Logistics / Supply Chain, Business Finance, Finance, Financial Operations, HR Operations, Operations, Risk
Partnership
Partnership, Product Management, Business Development
Partnership
Modalis Therapeutics News & Media
Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds.
TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases utilizing its proprietary CRISPR-GNDM® epigenome editing technology, announced its recognition as a top eight finalist in the prestigious XPRIZE Healthspan competition’s FSHD Bonus Prize and award of $250,000 for demonstrating a feasible solution to treat Facioscapulohumeral muscular dystrophy (FSHDJCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene Therapy
HYOGO, Japan & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TOKYO:4552; “JCR”) and Modalis Therapeutics Corporation (TOKYO:4883; “Modalis”) today announced that they have validated the initial proof of concept in a joint research program for the development of a novel gene therapy for a central nervous system (CNS) disease. Due to the success of the partnership thus far, Modalis and JCR have agreed to proceed to the next phase of their research by enteringModalis Therapeutics has received an Orphan Drug Designation from the U.S. Food and Drug Administration for MDL-101, a treatment for congenital muscular dystrophy type 1A (LAMA2-CMD).
TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883, CEO: Haru Morita), a leading company pioneering treatments for rare genetic diseases using its proprietary CRISPR-based epigenome editing technology, CRISPR-GNDM®, today announced that the U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) to MDL-101, a novel precision medicine being developed for the treatment of congenital muscular dystrophy type 1a (LAMA2-CModalis Therapeutics: FDA Grants Rare Pediatric Disease Designation to MDL-101 for the Treatment of Congenital Muscular Dystrophy Type 1a (LAMA2-CMD)
TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- #Crispr--Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883, CEO: Haru Morita), a leading company pioneering treatments for rare genetic diseases using its proprietary CRISPR-based epigenome editing technology, CRISPR-GNDM®, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to MDL-101, a novel precision medicine being developed for the treatment of congenital muscular dystrophy
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Modalis Therapeutics
Sign Up For FreeTo access detailed company insights
Modalis Therapeutics Corporation is a biotech company focused on developing treatments for genetic diseases using its proprietary genome editing platform, CRISPR-GNDM. The company specializes in epigenome editing technology that selectively targets and controls specific genes to treat diseases. Their innovative approach aims to restore the precise... Read More
